Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 14420
Country/Region: Zambia
Year: 2014
Main Partner: Lusaka Provincial Health Office
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $1,245,590 Additional Pipeline Funding: $1,798,742

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

Lusaka Provincial Health Office (LPHO) has the mandate to perform core public health activities within the Lusaka Province as part of the MOH with the key functions being supervision of services, policy interpretation, data management and technical support. The province notifies about one third of the total tuberculosis patients in the country (18,626 out of 48,000 in 2010). 70% of these patients are HIV infected. LPHO will expand the provision of ART to HIV infected clients and ensure that TB screening is provided at all service delivery areas. The Provincial Health Office will coordinate all treatment and care activities with the other USG funded partners in the province such as CIDRZ and Intrahealth. LPHO will strengthen the provision of care to HIV infected clients enrolled in HIV care programs. Cotrimoxazole prophylaxis will be provided for both adults and children. The province will continue with the provision of a complete package of PMTCT services in all districts focusing on strengthening quality of care, addressing missed opportunities and gaps in service delivery and in order to contribute to the MOH’s goal of elimination of MTCT. This will be achieved through ensuring the availability of the most efficacious regimens and provision of full HAART to all eligible women.These activities will be specifically designed to: Increase health worker retention in rural facilities for delivery of quality services; Increase utilization of maternity services; expand integration models for ANC and ART for increased coverage; Support development of integration models for PMTCT, pediatric HIV care, and routine MNCH services such as EPI, growth monitoring, nutritional support and post natal services.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $160,000
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $135,658
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Testing: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $699,932
Treatment: Pediatric Treatment (PDTX) $250,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
C2.1.D By Age: <15 2015 3,518
C2.1.D By Age: 15+ 2015 15,366
C2.1.D By Age/Sex: <15 Female 2015 594
C2.1.D By Age/Sex: <15 Male 2015 520
C2.1.D By Age/Sex: 15+ Female 2015 11,069
C2.1.D By Age/Sex: 15+ Male 2015 6,701
C2.1.D By Sex: Female 2015 11,663
C2.1.D By Sex: Male 2015 7,221
C2.1.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 18,884
C2.1.D Sum of Age disaggregates 2015 18,884
C2.1.D Sum of Age/Sex disaggregates 2015 18,884
C2.1.D Sum of Sex disaggregates 2015 18,884
C2.1.D_NGI By Age: <15 2015 3,518
C2.1.D_NGI By Age: 15+ 2015 15,366
C2.1.D_NGI By Age/Sex: <15 Female 2015 594
C2.1.D_NGI By Age/Sex: <15 Male 2015 520
C2.1.D_NGI By Age/Sex: 15+ Female 2015 11,069
C2.1.D_NGI By Age/Sex: 15+ Male 2015 6,701
C2.1.D_NGI By Sex: Female 2015 11,663
C2.1.D_NGI By Sex: Male 2015 7,221
C2.1.D_NGI Number of HIV-positive individuals receiving a minimum of one clinical service 2015 18,884
C2.1.D_NGI Sum of Age disaggregates 2015 18,884
C2.1.D_NGI Sum of Age/Sex disaggregates 2015 18,884
C2.1.D_NGI Sum of Sex disaggregates 2015 18,884
CARE_CURR Age/sex: <1 Female 2015 105
CARE_CURR Age/sex: <1 Male 2015 28
CARE_CURR Age/sex: 1-4 Female 2015 96
CARE_CURR Age/sex: 1-4 Male 2015 30
CARE_CURR Age/sex: 10-14 Female 2015 235
CARE_CURR Age/sex: 10-14 Male 2015 118
CARE_CURR Age/sex: 15-19 Female 2015 241
CARE_CURR Age/sex: 15-19 Male 2015 18
CARE_CURR Age/sex: 20-24 Female 2015 229
CARE_CURR Age/sex: 20-24 Male 2015 190
CARE_CURR Age/sex: 25-49 Female 2015 233
CARE_CURR Age/sex: 25-49 Male 2015 32
CARE_CURR Age/sex: 5-9 Female 2015 71
CARE_CURR Age/sex: 5-9 Male 2015 34
CARE_CURR Age/sex: 50+ Female 2015 185
CARE_CURR Age/sex: 50+ Male 2015 46
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 507
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 210
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 888
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 286
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 1,891
CARE_CURR Sum of Age/Sex disaggregates 2015 1,891
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2015 1,891
CARE_NEW Age/sex: <1 Female 2015 1,200
CARE_NEW Age/sex: <1 Male 2015 1,000
CARE_NEW Age/sex: 1-4 Female 2015 1,000
CARE_NEW Age/sex: 1-4 Male 2015 1,200
CARE_NEW Age/sex: 10-14 Female 2015 3,000
CARE_NEW Age/sex: 10-14 Male 2015 2,200
CARE_NEW Age/sex: 15-19 Female 2015 2,400
CARE_NEW Age/sex: 15-19 Male 2015 2,400
CARE_NEW Age/sex: 20-24 Female 2015 2,000
CARE_NEW Age/sex: 20-24 Male 2015 1,400
CARE_NEW Age/sex: 25-49 Female 2015 3,000
CARE_NEW Age/sex: 25-49 Male 2015 1,000
CARE_NEW Age/sex: 5-9 Female 2015 2,800
CARE_NEW Age/sex: 5-9 Male 2015 2,000
CARE_NEW Age/sex: 50+ Female 2015 2,000
CARE_NEW Age/sex: 50+ Male 2015 1,400
CARE_NEW Aggregated Age/sex: <15 Female 2015 10,000
CARE_NEW Aggregated Age/sex: <15 Male 2015 5,400
CARE_NEW Aggregated Age/sex: 15+ Female 2015 9,800
CARE_NEW Aggregated Age/sex: 15+ Male 2015 4,800
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 30,000
CARE_NEW Sum of Age/sex disaggregates 2015 30,000
CARE_NEW Sum of Aggregated Age/sex disaggregates 2015 30,000
CARE_SITE By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 46
CARE_SITE By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services 2015 48
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 46
CARE_SITE Sum of Numerator Site Support Type disaggregates 2015 46
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 48
CARE_SITE_den Sum of Denominator Site Support Type disaggregates 2015 48
HTS_TST Age/sex: <1 Female 2015 7,000
HTS_TST Age/sex: <1 Female 2015 7,000
HTS_TST Age/sex: <1 Male 2015 4,000
HTS_TST Age/sex: <1 Male 2015 4,000
HTS_TST Age/sex: 1-4 Female 2015 1,900
HTS_TST Age/sex: 1-4 Female 2015 1,900
HTS_TST Age/sex: 1-4 Male 2015 4,000
HTS_TST Age/sex: 1-4 Male 2015 4,000
HTS_TST Age/sex: 10-14 Female 2015 3,800
HTS_TST Age/sex: 10-14 Female 2015 3,800
HTS_TST Age/sex: 10-14 Male 2015 3,000
HTS_TST Age/sex: 10-14 Male 2015 3,000
HTS_TST Age/sex: 15-19 Female 2015 6,780
HTS_TST Age/sex: 15-19 Female 2015 6,780
HTS_TST Age/sex: 15-19 Male 2015 9,000
HTS_TST Age/sex: 15-19 Male 2015 9,000
HTS_TST Age/sex: 20-24 Female 2015 30,000
HTS_TST Age/sex: 20-24 Female 2015 30,000
HTS_TST Age/sex: 20-24 Male 2015 10,000
HTS_TST Age/sex: 20-24 Male 2015 10,000
HTS_TST Age/sex: 25-49 Female 2015 30,221
HTS_TST Age/sex: 25-49 Female 2015 30,221
HTS_TST Age/sex: 25-49 Male 2015 8,799
HTS_TST Age/sex: 25-49 Male 2015 8,799
HTS_TST Age/sex: 5-9 Female 2015 8,000
HTS_TST Age/sex: 5-9 Female 2015 8,000
HTS_TST Age/sex: 5-9 Male 2015 1,000
HTS_TST Age/sex: 5-9 Male 2015 1,000
HTS_TST Age/sex: 50+ Female 2015 19,000
HTS_TST Age/sex: 50+ Female 2015 19,000
HTS_TST Age/sex: 50+ Male 2015 3,500
HTS_TST Age/sex: 50+ Male 2015 3,500
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 30,000
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 35,000
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 45,000
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 40,000
HTS_TST Aggregated Age/sex: <15 Female 2015 30,000
HTS_TST Aggregated Age/sex: <15 Male 2015 35,000
HTS_TST Aggregated Age/sex: 15+ Female 2015 45,000
HTS_TST Aggregated Age/sex: 15+ Male 2015 40,000
HTS_TST By Test Result: Negative 2015 110,000
HTS_TST By Test Result: Negative 2015 110,000
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 150,000
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 150,000
HTS_TST Sum of Age/Sex disaggregates 2015 150,000
HTS_TST Sum of Age/Sex disaggregates 2015 150,000
HTS_TST Sum of Aggregated Age/Sex <15 2015 65,000
HTS_TST Sum of Aggregated Age/Sex <15 2015 65,000
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 85,000
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 85,000
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 150,000
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 150,000
HTS_TST Sum of Test Result disaggregates 2015 150,000
HTS_TST Sum of Test Result disaggregates 2015 150,000
HTS_TST_POS By Test Result: Positive 2015 40,000
HTS_TST_POS By Test Result: Positive 2015 40,000
LAB_ACC By site support type: Technical Assistance-only (TA) 2015 3
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 3
LAB_ACC Sum of Support Type disaggregates 2015 3
LAB_CAP By clinical laboratories 2015 12
LAB_CAP By Point-of-care testing sites 2015 15
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 27
LAB_CAP By site support type: Technical Assistance-only (TA) 2015 3
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 32
LAB_CAP Sum of Site Support Type disaggregates 2015 30
PMTCT_ARV Life-long ART (including Option B+) 2015 4,080
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 2,290
PMTCT_ARV Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 490
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 4,244
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 4,080
PMTCT_ARV Single-dose nevirapine (with or without tail) 2015 145
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 2,042
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 2,038
PMTCT_ARV Sum of New and Current disaggregates 2015 4,080
PMTCT_ARV Sum of Regimen Type disaggregates 2015 7,005
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 4,080
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 2,290
PMTCT_ARV_NGI Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 490
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 4,244
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 4,080
PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 2015 145
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 2,042
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 2,038
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 4,080
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 7,005
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 1,218
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 1,456
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 30
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 3,244
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 2,674
PMTCT_EID Sum of Infant Age disaggregates 2015 2,674
PMTCT_SITE By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 70
PMTCT_SITE By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 70
PMTCT_SITE Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 70
PMTCT_SITE Sum of Numerator Support Type disaggregates 2015 149
PMTCT_SITE Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 70
PMTCT_SITE_den Sum of Denominator Support Type disaggregates 2015 149
PMTCT_STAT By: Known positives at entry 2015 591
PMTCT_STAT By: Known positives at entry 2015 836
PMTCT_STAT By: Number of new positives identified 2015 885
PMTCT_STAT By: Number of new positives identified 2015 1,254
PMTCT_STAT Number of new ANC and L&D clients 2015 29,338
PMTCT_STAT Number of new ANC and L&D clients 2015 20,000
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 24,828
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 19,000
PMTCT_STAT Sum of Positives Status disaggregates 2015 1,476
PMTCT_STAT Sum of Positives Status disaggregates 2015 2,090
PMTCT_STAT_NGI By: Known positives at entry 2015 591
PMTCT_STAT_NGI By: Number of new positives identified 2015 885
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 29,338
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 24,828
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 1,476
PP_PREV Age/sex: 10-14 Female 2015 2,300
PP_PREV Age/sex: 10-14 Male 2015 2,500
PP_PREV Age/sex: 15-19 Female 2015 3,000
PP_PREV Age/sex: 15-19 Male 2015 3,000
PP_PREV Age/sex: 20-24 Female 2015 3,700
PP_PREV Age/sex: 20-24 Male 2015 3,100
PP_PREV Age/sex: 25-49 Female 2015 4,500
PP_PREV Age/sex: 25-49 Male 2015 2,900
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 25,000
PP_PREV Sum of Age/Sex disaggregates 2015 25,000
PP_PREV Total number of people in the target population 2015 35,000
SITE_SUPP By program area/support type: Care and Support Technical Assistance-only (TA) 2015 55
SITE_SUPP By program area/support type: General Population Prevention Technical Assistance-only (TA) 2015 90
SITE_SUPP By program area/support type: HTC Technical Assistance-only (TA) 2015 104
SITE_SUPP By program area/support type: Lab Technical Assistance-only (TA) 2015 32
SITE_SUPP By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA) 2015 90
SITE_SUPP By program area/support type: PMTCT Technical Assistance-only (TA) 2015 70
SITE_SUPP By program area/support type: TB/HIV Technical Assistance-only (TA) 2015 45
SITE_SUPP By program area/support type: Treatment Technical Assistance-only (TA) 2015 55
SITE_SUPP By program area/support type: VMMC Technical Assistance-only (TA) 2015 25
SITE_SUPP Number of unique sites supported by PEPFAR 2015 104
TB_ART Age: 0-4 2015 100
TB_ART Age: 15+ 2015 1,900
TB_ART Age: 5-14 2015 1,500
TB_ART Aggregated Age: <15 2015 28
TB_ART Aggregated Age: 15+ 2015 3,472
TB_ART Female 2015 2,100
TB_ART Known HIV-positive 2015 2,500
TB_ART Male 2015 1,400
TB_ART Newly tested 2015 1,000
TB_ART Sum of Aggregated Age disaggregates 2015 3,500
TB_ART Sum of Sex disaggregates 2015 3,500
TB_ART Sum of Test Status disaggregates 2015 3,500
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2015 26,496
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2015 3,500
TB_ARTSITE By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units 2015 20
TB_ARTSITE By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units 2015 35
TB_ARTSITE By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 35
TB_ARTSITE Sum of Numerator Site Support Type disaggregates 2015 35
TB_ARTSITE The number of PEPFAR-supported TB basic management units 2015 35
TB_ARTSITE The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 35
TB_ARTSITE_den Sum of Denominator Site Support Type disaggregates 2015 55
TB_SCREEN Age: 1-4 2015 1,250
TB_SCREEN Age: 10-14 2015 4,700
TB_SCREEN Age: 15-19 2015 4,500
TB_SCREEN Age: 20-24 2015 10,000
TB_SCREEN Age: 25-49 2015 10,000
TB_SCREEN Age: 5-9 2015 3,500
TB_SCREEN Age: 50+ 2015 12,000
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2015 9,500
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2015 36,500
TB_SCREEN Sex: Female 2015 27,600
TB_SCREEN Sex: Male 2015 18,400
TB_SCREEN Sum of Age disaggregates 2015 14,000
TB_SCREEN Sum of Aggregated Age disaggregates 2015 46,000
TB_SCREEN Sum of Sex disaggregates 2015 46,000
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 25,253
TX_CURR Age/Sex: <1 Female 2015 28
TX_CURR Age/Sex: <1 Male 2015 52
TX_CURR Age/Sex: 1-4 Female 2015 125
TX_CURR Age/Sex: 1-4 Male 2015 128
TX_CURR Age/Sex: 15+ Female 2015 7,935
TX_CURR Age/Sex: 15+ Male 2015 4,439
TX_CURR Age/Sex: 5-14 Female 2015 404
TX_CURR Age/Sex: 5-14 Male 2015 552
TX_CURR Aggregated Age/Sex: <1 Female 2015 28
TX_CURR Aggregated Age/Sex: <1 Male 2015 52
TX_CURR Aggregated Age/Sex: <15 Female 2015 557
TX_CURR Aggregated Age/Sex: <15 Male 2015 732
TX_CURR Aggregated Age/Sex: 15+ Female 2015 7,935
TX_CURR Aggregated Age/Sex: 15+ Male 2015 4,439
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 13,663
TX_CURR Sum of Age/Sex disaggregations 2015 1,289
TX_CURR Sum of Aggregated Age/Sex <15 2015 1,289
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 12,374
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 13,663
TX_CURR_NGI Age/Sex: <1 Female 2015 28
TX_CURR_NGI Age/Sex: <1 Male 2015 52
TX_CURR_NGI Age/Sex: 1-4 Female 2015 125
TX_CURR_NGI Age/Sex: 1-4 Male 2015 128
TX_CURR_NGI Age/Sex: 15+ Female 2015 7,935
TX_CURR_NGI Age/Sex: 15+ Male 2015 4,439
TX_CURR_NGI Age/Sex: 5-14 Female 2015 404
TX_CURR_NGI Age/Sex: 5-14 Male 2015 552
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 28
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 52
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 557
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 732
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 7,935
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 4,439
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 13,663
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 13,663
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 1,289
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 12,374
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 13,663
TX_DIST Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District 2015 8
TX_DIST Total number of PEPFAR supported District Health Offices 2015 8
TX_NEW Aggregated Grouping by Age: <1 Male 2015 1,003
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 1,001
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 4,099
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 4,091
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 21,907
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 4,553
TX_NEW Breastfeeding status 2015 21,907
TX_NEW By Age/Sex: <1 Female 2015 1,001
TX_NEW By Age/Sex: <1 Male 2015 1,003
TX_NEW By Age/Sex: 1-4 Female 2015 1,009
TX_NEW By Age/Sex: 1-4 Male 2015 1,007
TX_NEW By Age/Sex: 10-14 Female 2015 1,063
TX_NEW By Age/Sex: 10-14 Male 2015 1,064
TX_NEW By Age/Sex: 15-19 Female 2015 7,203
TX_NEW By Age/Sex: 15-19 Male 2015 1,090
TX_NEW By Age/Sex: 20-24 Female 2015 7,202
TX_NEW By Age/Sex: 20-24 Male 2015 1,085
TX_NEW By Age/Sex: 25-49 Female 2015 7,302
TX_NEW By Age/Sex: 25-49 Male 2015 1,313
TX_NEW By Age/Sex: 5-9 Female 2015 1,026
TX_NEW By Age/Sex: 5-9 Male 2015 1,017
TX_NEW By Age/Sex: 50+ Female 2015 200
TX_NEW By Age/Sex: 50+ Male 2015 1,065
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 34,650
TX_NEW Pregnancy status 2015 21,907
TX_NEW Sum of Age/Sex disaggregates 2015 34,650
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 34,650
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,333
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 3,022
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,220
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 16,832
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 2,200
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 7,000
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 5,575
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 30,000
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 2,233
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 11,343
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 3,256
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 2,553
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 3,022
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 5,575
TX_SITE By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 35
TX_SITE By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites 2015 44
TX_SITE Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 35
TX_SITE Sum of Numerator Site Support Type disaggregates 2015 35
TX_SITE Total number of PEPFAR-supported ART sites 2015 44
TX_SITE_den Sum of Denominator Site Support Type disaggregates 2015 44
VMMC_AE By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s) 2015 80
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2015 80
VMMC_CIRC By Age: <1 2015 541
VMMC_CIRC By Age: 1-9 2015 1,295
VMMC_CIRC By Age: 10-14 2015 1,550
VMMC_CIRC By Age: 15-19 2015 1,350
VMMC_CIRC By Age: 20-24 2015 1,410
VMMC_CIRC By Age: 25-49 2015 1,201
VMMC_CIRC By Age: 50+ 2015 35
VMMC_CIRC By circumcision technique: Device-based VMMC 2015 768
VMMC_CIRC By circumcision technique: Surgical VMMC 2015 7,382
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 5,905
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2015 2,378
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 4,472
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 532
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 7,382
VMMC_CIRC Sum of Age disaggregations 2015 7,382
VMMC_CIRC_NGI By Age: <1 2015 541
VMMC_CIRC_NGI By Age: 1-9 2015 1,295
VMMC_CIRC_NGI By Age: 10-14 2015 1,550
VMMC_CIRC_NGI By Age: 15-19 2015 1,350
VMMC_CIRC_NGI By Age: 20-24 2015 1,410
VMMC_CIRC_NGI By Age: 25-49 2015 1,201
VMMC_CIRC_NGI By Age: 50+ 2015 35
VMMC_CIRC_NGI By circumcision technique: Device-based VMMC 2015 768
VMMC_CIRC_NGI By circumcision technique: Surgical VMMC 2015 7,382
VMMC_CIRC_NGI By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 5,905
VMMC_CIRC_NGI By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2015 2,378
VMMC_CIRC_NGI By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 4,472
VMMC_CIRC_NGI By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 532
VMMC_CIRC_NGI Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 7,382
VMMC_CIRC_NGI Sum of Age disaggregates 2015 7,382
Cross Cutting Budget Categories and Known Amounts Total: $345,000
Renovation $50,000
Motor Vehicles: Purchased $285,000
Water $10,000
Key Issues Identified in Mechanism
enumerations.Malaria (PMI)
Child Survival Activities
Mobile Populations
Safe Motherhood
Tuberculosis
Workplace Programs
Family Planning